Details for Patent: 8,629,128
✉ Email this page to a colleague
Which drugs does patent 8,629,128 protect, and when does it expire?
Patent 8,629,128 protects SORILUX and is included in one NDA.
This patent has twenty-eight patent family members in thirteen countries.
Summary for Patent: 8,629,128
| Title: | Vitamin formulation |
| Abstract: | A pharmaceutical aerosol foam composition, comprising: an effective amount of a pharmaceutically active ingredient, wherein said pharmaceutically active ingredient is a vitamin or analogue thereof; an occlusive agent; an aqueous solvent; an organic cosolvent; wherein the pharmaceutically active ingredient is insoluble in both water and the occlusive agent; and the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use. In a second embodiment, an oil-in water emulsion having a vitamin, an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin. |
| Inventor(s): | Buchta; Richard (Rowville, AU), Houlden; Robert James (Rowville, AU), Larm; Maria Graziella (Rowville, AU), Loupenok; Leon (Rowville, AU), Ye; Rose (Rowville, AU) |
| Assignee: | Stiefel West Coast, LLC (Wilmington, New Castle, DE) |
| Application Number: | 13/623,568 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
More… ↓ |
Drugs Protected by US Patent 8,629,128
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma | SORILUX | calcipotriene | AEROSOL, FOAM;TOPICAL | 022563-001 | Oct 6, 2010 | RX | Yes | Yes | 8,629,128 | ⤷ Subscribe | Y | USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS | ⤷ Subscribe | |||
| Mayne Pharma | SORILUX | calcipotriene | AEROSOL, FOAM;TOPICAL | 022563-001 | Oct 6, 2010 | RX | Yes | Yes | 8,629,128 | ⤷ Subscribe | Y | USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER | ⤷ Subscribe | |||
| Mayne Pharma | SORILUX | calcipotriene | AEROSOL, FOAM;TOPICAL | 022563-001 | Oct 6, 2010 | RX | Yes | Yes | 8,629,128 | ⤷ Subscribe | Y | USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 4 YEARS AND OLDER | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,629,128
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E381315 | ⤷ Subscribe | |||
| Australia | 2006253913 | ⤷ Subscribe | |||
| Australia | 6069299 | ⤷ Subscribe | |||
| Australia | 760153 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
